Pfizer Shares Up 1.29%, Active Options Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy PFE?
Moderately bullish activity in Pfizer (PFE), with shares up 34c, or 1.29%, near $27.02. Options volume running well above average with 164k contracts traded and calls leading puts for a put/call ratio of 0.31, compared to a typical level near 0.55. Implied volatility (IV30) is higher by 0.9 points near 25.94,and above the 52wk median, suggesting an expected daily move of $0.44. Put-call skew flattened, suggesting a modestly bullish tone.Looking ahead: Pfizer (PFE) will report earnings before the open on 2026-05-05.Option markets are pricing in a 50% probability of a move greater than 3.11% or $0.84.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.480
Low
24.00
Averages
28.56
High
35.00
Current: 26.480
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High-Yield Stock Investment Opportunities
- Pfizer's Outlook: Pfizer boasts a forward dividend yield of 6.4%, and despite facing poor financial results and increased competition, its robust portfolio of medicines and the launch of new products are expected to support dividend sustainability, particularly with significant sales growth from the 2023-approved Abrysvo vaccine and Elrexfio cancer drug.
- Medical Properties Trust's Challenges: Medical Properties Trust (MPT) has faced tenant defaults and bankruptcies over the past few years; however, the company has successfully diversified by cutting dividends and selling assets, thereby reducing reliance on any single tenant and enhancing long-term stability.
- Dividend Safety Analysis: Despite an uncertain economic outlook, MPT's forward dividend yield stands at 7%, and medical-focused REITs are considered relatively safe; MPT's management has expressed confidence in the recovery of its business and announced a dividend increase last year, demonstrating a commitment to shareholder returns.
- Long-Term Investment Appeal: Although MPT's stock has significantly declined over the past three years, it remains well-positioned for strong performance as its business stabilizes, making it an attractive high-yield stock choice for income-seeking investors.
See More
PFIZER: JEFFERIES INCREASES TARGET PRICE TO $35, UP FROM $34
- Pfizer's Price Adjustment: Pfizer has raised the price of its medication, Jeffries, from $34 to $35.
- Market Impact: This price increase may influence market dynamics and consumer access to the medication.
See More
Pfizer and Medical Properties Trust's Dividend Outlook
- Pfizer's Dividend Appeal: With a forward dividend yield of 6.4%, Pfizer faces challenges from poor financial results and stiff competition; however, its deep portfolio and new product launches support the sustainability of its dividends.
- New Drug Sales Growth: Pfizer's Abrysvo vaccine generated $1 billion in sales in 2023, a 37% increase year-over-year, while Elrexfio's revenue rose from $103 million in 2024 to $304 million, indicating positive progress in its drug development efforts.
- Medical Properties Trust's Recovery: After facing tenant defaults and bankruptcies, Medical Properties Trust diversified its operations through dividend cuts and asset sales; despite a significant stock price drop over the past three years, its 7% high dividend yield suggests a positive outlook in the defensive healthcare sector.
- Long-Term Investment Appeal: Medical Properties Trust demonstrates strong recovery potential amid economic uncertainty, and as its business stabilizes, it is well-positioned for long-term performance, making it an attractive option for income-seeking investors.
See More
Pfizer Settles Patent Disputes with Generic Manufacturers
- Settlement Agreements: Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd. to resolve patent infringement lawsuits over Vyndamax, effectively extending U.S. patent exclusivity to June 1, 2031, thus averting a significant sales drop anticipated in 2029.
- Market Reaction: Morgan Stanley noted that the settlement is at the lower end of investor expectations, leading to a slight decline in Pfizer's shares, while rival BridgeBio's stock fell 6%, indicating cautious market sentiment towards Pfizer's resolution.
- Revenue Stability Outlook: Pfizer expects Vyndamax revenues to remain relatively stable from 2028 through mid-2031 due to the settlement preventing earlier generic entry, thereby preserving its 75% prescription volume share in the ATTR-CM market.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around BridgeBio stock surged from 'bullish' to 'extremely bullish', while Pfizer's sentiment remained neutral, reflecting investors' sensitivity to market developments.
See More
Pfizer Faces Challenges and Opportunities Ahead
- Patent Expiration Risks: Pfizer faces the imminent loss of patent protection on multiple drugs, which could lead to revenue declines, particularly as competition intensifies, posing pressure on the company's future growth.
- Stock Price Decline and Attractive Valuation: With a stock price drop of over 30% in the past five years, Pfizer's current market cap stands at $152 billion, and its 6.4% dividend yield offers an attractive proposition for investors despite the challenges ahead.
- Growth Strategy and Acquisitions: CEO Albert Bourla outlined a strategy to add $25 billion in revenue by 2030 through acquisitions and in-house development, yet investor skepticism remains high regarding its feasibility, especially in light of increasing generic competition.
- Drug Development Potential: With over 100 drug candidates in its pipeline, Pfizer may not have immediate breakthroughs, but successful approvals could significantly enhance market performance, presenting long-term investment opportunities.
See More
Pfizer Settles Patent Lawsuits with Generic Drug Makers
- Settlement Agreements: Pfizer has entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, extending the patent expiry date for VYNDAMAX to June 1, 2031, which stabilizes expected revenues and mitigates the anticipated decline starting in 2029.
- Market Leadership: VYNDAMAX commands a 75% share of the ATTR-CM prescription market, being the only once-daily capsule approved for this condition, demonstrating significant reductions in all-cause mortality and cardiovascular-related hospitalizations, thereby reinforcing Pfizer's competitive edge.
- Enhanced Patient Care: Pfizer's decision to discontinue VYNDAQEL in the U.S. focuses on VYNDAMAX, aiming to improve patient convenience and adherence through a single daily capsule, particularly beneficial for patients with multiple concurrent conditions requiring various oral medications.
- Commitment to Innovation: Pfizer executives highlighted that the settlement outcome not only recognizes the value of innovative science but also underscores the company's unwavering commitment to ATTR-CM patients, which is expected to further enhance VYNDAMAX's market penetration and patient reach.
See More
Analysis of High-Yield Stock Investment Opportunities
- Pfizer's Outlook: Pfizer boasts a forward dividend yield of 6.4%, and despite facing poor financial results and increased competition, its robust portfolio of medicines and the launch of new products are expected to support dividend sustainability, particularly with significant sales growth from the 2023-approved Abrysvo vaccine and Elrexfio cancer drug.
- Medical Properties Trust's Challenges: Medical Properties Trust (MPT) has faced tenant defaults and bankruptcies over the past few years; however, the company has successfully diversified by cutting dividends and selling assets, thereby reducing reliance on any single tenant and enhancing long-term stability.
- Dividend Safety Analysis: Despite an uncertain economic outlook, MPT's forward dividend yield stands at 7%, and medical-focused REITs are considered relatively safe; MPT's management has expressed confidence in the recovery of its business and announced a dividend increase last year, demonstrating a commitment to shareholder returns.
- Long-Term Investment Appeal: Although MPT's stock has significantly declined over the past three years, it remains well-positioned for strong performance as its business stabilizes, making it an attractive high-yield stock choice for income-seeking investors.
See More
PFIZER: JEFFERIES INCREASES TARGET PRICE TO $35, UP FROM $34
- Pfizer's Price Adjustment: Pfizer has raised the price of its medication, Jeffries, from $34 to $35.
- Market Impact: This price increase may influence market dynamics and consumer access to the medication.
See More
Pfizer and Medical Properties Trust's Dividend Outlook
- Pfizer's Dividend Appeal: With a forward dividend yield of 6.4%, Pfizer faces challenges from poor financial results and stiff competition; however, its deep portfolio and new product launches support the sustainability of its dividends.
- New Drug Sales Growth: Pfizer's Abrysvo vaccine generated $1 billion in sales in 2023, a 37% increase year-over-year, while Elrexfio's revenue rose from $103 million in 2024 to $304 million, indicating positive progress in its drug development efforts.
- Medical Properties Trust's Recovery: After facing tenant defaults and bankruptcies, Medical Properties Trust diversified its operations through dividend cuts and asset sales; despite a significant stock price drop over the past three years, its 7% high dividend yield suggests a positive outlook in the defensive healthcare sector.
- Long-Term Investment Appeal: Medical Properties Trust demonstrates strong recovery potential amid economic uncertainty, and as its business stabilizes, it is well-positioned for long-term performance, making it an attractive option for income-seeking investors.
See More
Pfizer Settles Patent Disputes with Generic Manufacturers
- Settlement Agreements: Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd. to resolve patent infringement lawsuits over Vyndamax, effectively extending U.S. patent exclusivity to June 1, 2031, thus averting a significant sales drop anticipated in 2029.
- Market Reaction: Morgan Stanley noted that the settlement is at the lower end of investor expectations, leading to a slight decline in Pfizer's shares, while rival BridgeBio's stock fell 6%, indicating cautious market sentiment towards Pfizer's resolution.
- Revenue Stability Outlook: Pfizer expects Vyndamax revenues to remain relatively stable from 2028 through mid-2031 due to the settlement preventing earlier generic entry, thereby preserving its 75% prescription volume share in the ATTR-CM market.
- Investor Sentiment Shift: On Stocktwits, retail sentiment around BridgeBio stock surged from 'bullish' to 'extremely bullish', while Pfizer's sentiment remained neutral, reflecting investors' sensitivity to market developments.
See More
Pfizer Faces Challenges and Opportunities Ahead
- Patent Expiration Risks: Pfizer faces the imminent loss of patent protection on multiple drugs, which could lead to revenue declines, particularly as competition intensifies, posing pressure on the company's future growth.
- Stock Price Decline and Attractive Valuation: With a stock price drop of over 30% in the past five years, Pfizer's current market cap stands at $152 billion, and its 6.4% dividend yield offers an attractive proposition for investors despite the challenges ahead.
- Growth Strategy and Acquisitions: CEO Albert Bourla outlined a strategy to add $25 billion in revenue by 2030 through acquisitions and in-house development, yet investor skepticism remains high regarding its feasibility, especially in light of increasing generic competition.
- Drug Development Potential: With over 100 drug candidates in its pipeline, Pfizer may not have immediate breakthroughs, but successful approvals could significantly enhance market performance, presenting long-term investment opportunities.
See More
Pfizer Settles Patent Lawsuits with Generic Drug Makers
- Settlement Agreements: Pfizer has entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, extending the patent expiry date for VYNDAMAX to June 1, 2031, which stabilizes expected revenues and mitigates the anticipated decline starting in 2029.
- Market Leadership: VYNDAMAX commands a 75% share of the ATTR-CM prescription market, being the only once-daily capsule approved for this condition, demonstrating significant reductions in all-cause mortality and cardiovascular-related hospitalizations, thereby reinforcing Pfizer's competitive edge.
- Enhanced Patient Care: Pfizer's decision to discontinue VYNDAQEL in the U.S. focuses on VYNDAMAX, aiming to improve patient convenience and adherence through a single daily capsule, particularly beneficial for patients with multiple concurrent conditions requiring various oral medications.
- Commitment to Innovation: Pfizer executives highlighted that the settlement outcome not only recognizes the value of innovative science but also underscores the company's unwavering commitment to ATTR-CM patients, which is expected to further enhance VYNDAMAX's market penetration and patient reach.
See More
